Table 1.

Patients characteristics.

PTS	Start TX	Age	Sex	Arm	Site/N°	T. necrosis	PgP on Met.	PRDFS	OS (ms)	Outcome	Status 30.6.19
1	08/06/07	48	F	Viscum P	Lung one	NA	NE	144	144	NED	NED
2	03/09/07	18	F	Viscum P	Lung two	PR	Pos	134	134	NED	NED
3	02/10/07	28	M	Viscum P	Lung two	GR	Pos	140	140	NED	NED
4	21/04/08	29	M	Viscum P	Lung one	GR	NA	3	17	R	Dead
5	19/09/08	30	F	Viscum P	Lung two	PR	NE	121	121	NED	NED
6	23/09/08	21	F	Viscum P	Lung three	PR	Neg	6	120	R	NED1
7	02/04/10	20	F	Viscum P	Bone one	PR	Neg	106	106	NED	NED
8	23/07/10	41	M	Viscum P	Lung one	GR	NE	2	24	R	Dead
9	30/06/11	22	M	Viscum P	Lung one	GR	Neg	11	36	R	Dead
10	12/06/07	28	M	Etoposide	Bone one	PR	NA	3	5	R	Dead
11	17/01/08	62	F	Etoposide	Lung one	GR	NA	12	128	R	NED 1
12	17/01/08	48	M	Etoposide	Lung one	PR	NE	6	134	R	NED 1
13	17/03/08	16	F	Etoposide	Lung one	GR	Neg	3	5	R	Dead
14	07/01/09	11	M	Etoposide	Lung two	GR	Neg	1	3	R	Dead
15	10/07/09	35	F	Etoposide	Lung one	NA	Neg	9	118	R	NED 1
16	28/05/09	65	M	Etoposide	Lung two	NA	Neg	84	119	R	NED 1
17	11/02/10	17	M	Etoposide	Lung two	PR	Pos	4	25	R	Dead
18	11/05/10	63	M	Etoposide	Lung one	NA	Pos	42	60	R	Dead
19	08/07/11	17	F	Etoposide	Lung two	PR	Neg	8	23	R	Dead
20	08/08/11	67	M	Etop never started ITT NA 43	NE	Dead	ITT

Site/N° = site of the 2^nd metastase, N of lesions; tumor necrosis: necrosis on primary tumor; GR = good responder > 90% and PR = poor responder ≤ 90%; PgP on metastases: pos = Positive, Neg = Negative; NA = not available and NE = not evaluable; NED = nonevidence of disease after enrollment: NED1 = nonevidence of disease after treatment for a third relapse; R = relapse; ITT = intention-to-treat; PRDFS: postrelapse disease-free survival; OS: overall survival.